Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Sarah Grillo/Axios

Better screening and increased drug research into new antibiotics and antiviral medications are greatly needed to head off what some health experts say could be a future in which there will be no effective medications to fight common infections like gonorrhea, syphilis, E. coli and staph.

Why it matters: Antimicrobial resistance is currently projected to be the number one killer by 2050 — "outpacing even cancer" — according to Amy Mathers, assistant professor at the University of Virginia School of Medicine.

The specter of increasingly drug-resistant diseases made news this week when CDC officials announced America reached a record high of new cases of sexually transmitted diseases. They also warned of increasing signs that one of the most common STDs, gonorrhea, is becoming more resistant to front-line antibiotics.

The threat: This disease has proven to be a "smart bug," developing resistance to multiple antibodies in the past, Elizabeth Torrone, who leads surveillance and special studies for CDC’s Division of STD Prevention, tells Axios.

  • If left untreated, gonorrhea can cause infertility, miscarriages, chronic pain and blindness in newborns.
  • Currently, there's one last antibiotic (ceftriaxone) that remains effective against the disease.
  • It's often prescribed as a dual therapy, with a single shot of ceftriaxone plus an oral dose of a second antibiotic (azithromycin), in an attempt to preserve the ceftriaxone's effectiveness, Torrone says.
  • CDC officials warned they recently found an uptick in the portion of lab samples showing resistance to azithromycin — from 1% in 2013 to 4% in 2017.

Despite being a small percentage, this is a concern because genes from the resistant strains could crossover with gonorrhea genes and reduce its susceptibility to ceftriaxone, Torrone says.

Be smart: On the STD front, better and more frequent testing is needed to prevent the spread of the diseases in the first place, says Ursula Hessenflow, co-founder of myLAB Box, which offers home DNA testing for HPV, chlamydia, gonorrhea, syphilis, herpes and others. Hessenflow tells Axios:

"A big problem in the U.S. is people are simply avoiding STD testing in the first place. Failure to stem these infections includes lack of sex education, the cost, shame and inconvenience of regular testing in a lab, clinic or doctor’s office, and the fact that [STD] still carries great taboo."

What's needed is both better diagnostic testing and the development of new antibiotics, Mathers says. She says next-generation sequencing is where testing should head, so that physicians know which specific antibiotic is best to prescribe, instead of having the patient take multiple ones. Plus, she adds, this can help track antibiotic resistance more carefully.

The big picture: Gonorrhea is far from the only disease that scientists around the world are keeping a close eye on for antimicrobial resistance. Other diseases with growing resistance include syphilis, E. coli (particularly in urinary tract infections), methicillin-resistant Staphylococcus aureus (MRSA), tuberculosis and malaria, Mathers and Torrone say.

"This is a complicated problem," Mathers says. More antibiotic resistance research is needed not only in people, but also the role resistance plays in other areas like animal husbandry and wastewater.

"It's gotten much harder to treat patients over the last 10 years [due to antibiotic concerns]," Mathers says.

Go deeper

CDC lets child migrant shelters fill to 100% despite COVID concern

Intensive care tents at overflow shelter in Carrizo Springs, Texas. Photo: Sergio Flores/The Washington Post via Getty Images

The Centers for Disease Control is allowing shelters handling child migrants who cross the U.S.-Mexico border to expand to full capacity, abandoning a requirement that they stay near 50% to inhibit the spread of the coronavirus, Axios has learned.

Why it matters: The fact that the country's premier health advisory agency is permitting a change in COVID-19 protocols indicates the scale of the immigration crisis. A draft memo obtained by Axios conceded "facilities should plan for and expect to have COVID-19 cases."

8 Senate Democrats vote against adding $15 minimum wage to COVID relief

Photo: Stefani Reynolds/Bloomberg via Getty Images

Eight Democratic senators on Friday voted against Sen. Bernie Sanders' amendment to ignore a ruling by the Senate parliamentarian and add a $15 minimum wage provision to the $1.9 trillion COVID relief package.

The state of play: The vote was held open for hours on Friday afternoon — even after every senator had voted — due to a standoff in negotiations over the next amendments that the Senate will take up.

CDC: Easing mask mandates led to higher COVID cases and deaths

Customer at a supermarket chain in Austin, Texas. Montinique Monroe/Getty Images

Easing mask restrictions and on-site dining have increased COVID-19 cases and deaths, according to a study out Friday from the Centers for Disease Control and Prevention.

Why it matters: The report's findings converge with actions from governors this week easing mask mandates and announcing plans to reopen nonessential businesses like restaurants.